Download data/table_catalog.json from kipasyangin5/mva-syndrome-exploreraaaa: direct link, hf CLI and curl.
- Browser
- Download file 107 kB
-
https://huggingface.co/spaces/kipasyangin5/mva-syndrome-exploreraaaa/resolve/main/data/table_catalog.json
- Command line
-
hf download hf://spaces/kipasyangin5/mva-syndrome-exploreraaaa/data/table_catalog.json
-
curl -L -o table_catalog.json https://huggingface.co/spaces/kipasyangin5/mva-syndrome-exploreraaaa/resolve/main/data/table_catalog.json
107 kB
| { | |
| "total_tables": 235, | |
| "categories": [ | |
| "Clinical & Phenomics", | |
| "Chromosome Architecture", | |
| "Gene Panels & Interactome", | |
| "Mosaicism Spectrum", | |
| "ACMG & In Silico Predictors", | |
| "Precision Oncology & Pharma", | |
| "Cytogenetics & Aneuploidy", | |
| "Sequencing & Flowcell QC", | |
| "Biophysical Kinetics", | |
| "Comparative Oncology Cohorts" | |
| ], | |
| "tables": [ | |
| { | |
| "id": "clin_01_hpo_ontological_ic", | |
| "category": "Clinical & Phenomics", | |
| "title": "HPO Ontological Hierarchy & Information Content Scoring", | |
| "description": "Ontological ancestry paths and calculated Information Content (IC) for proband clinical manifestations.", | |
| "row_count": 8, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_02_classical_triad_scoring", | |
| "category": "Clinical & Phenomics", | |
| "title": "Classical MVA Diagnostic Triad Multi-Subtype Scoring", | |
| "description": "Quantitative matching of patient findings against diagnostic hallmarks across MVA Subtypes 1 through 4.", | |
| "row_count": 5, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_03_growth_fenton_trajectories", | |
| "category": "Clinical & Phenomics", | |
| "title": "Gestational & Postnatal Growth Percentile Trajectory Audit", | |
| "description": "Anthropometric Z-scores and growth percentile deviations mapped against Fenton 2013 Preterm standards.", | |
| "row_count": 5, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_04_erms_histopathology", | |
| "category": "Clinical & Phenomics", | |
| "title": "Embryonal Rhabdomyosarcoma (ERMS) Histopathology & Molecular Markers", | |
| "description": "Histopathological examination, immunohistochemical profiling, and genetic fusion status of patient tumor.", | |
| "row_count": 6, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_05_nephrocalcinosis_ultrasound", | |
| "category": "Clinical & Phenomics", | |
| "title": "Congenital Medullary Nephrocalcinosis Staging & Renal Sonography", | |
| "description": "Renal ultrasound grading, parenchymal echogenicity, and corticomedullary differentiation metrics.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_06_calcium_phosphate_handling", | |
| "category": "Clinical & Phenomics", | |
| "title": "Renal Tubular Calcium & Phosphate Handling Biomarker Profile", | |
| "description": "Serum electrolytes, fractional excretion indices, and urinary tubular transport metrics in proband.", | |
| "row_count": 6, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_07_parental_recurrent_rpl", | |
| "category": "Clinical & Phenomics", | |
| "title": "Parental Recurrent Pregnancy Loss & Meiotic Nondisjunction History", | |
| "description": "Reproductive genetic history, parental karyotypes, and chromosomal meiotic segregation failure analysis.", | |
| "row_count": 4, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_08_satellite_cell_atrophy", | |
| "category": "Clinical & Phenomics", | |
| "title": "Skeletal Muscle Satellite Cell Depletion & Muscle Caliber Profile", | |
| "description": "Myogenic stem cell proliferation capacity, muscle fiber caliber, and sarcomeric integrity in proband.", | |
| "row_count": 4, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_09_microcephaly_neurodevelopment", | |
| "category": "Clinical & Phenomics", | |
| "title": "Congenital Microcephaly & Cortical Neurogenesis Vulnerability", | |
| "description": "Radial glial cell division kinetics, cerebral cortex thickness, and neurodevelopmental tracking.", | |
| "row_count": 4, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_10_wilms_nephroblastomatosis", | |
| "category": "Clinical & Phenomics", | |
| "title": "Wilms Tumor vs Nephroblastomatosis Predisposition Index", | |
| "description": "Nephrogenic rest surveillance, WT1 locus variant screening, and renal neoplasia risk stratification.", | |
| "row_count": 3, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_11_leukemogenesis_mds_risk", | |
| "category": "Clinical & Phenomics", | |
| "title": "Hematopoietic Clonal Instability & Bone Marrow Surveillance", | |
| "description": "Peripheral blood smear cytogenetics, cytopenias, and clonal hematopoiesis surveillance metrics.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_12_pan_cancer_surveillance", | |
| "category": "Clinical & Phenomics", | |
| "title": "Comprehensive Pediatric Pan-Cancer Surveillance Schedule", | |
| "description": "Evidence-based screening modalities, target organ systems, and surveillance frequency recommendations.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_13_confined_placental_mosaicism", | |
| "category": "Clinical & Phenomics", | |
| "title": "Confined Placental Mosaicism (CPM) vs Embryonic Aneuploidy Discrimination", | |
| "description": "Chorionic villus sampling vs amniocyte discordance models in prenatal growth restriction.", | |
| "row_count": 3, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_14_gh_igf1_endocrine_axis", | |
| "category": "Clinical & Phenomics", | |
| "title": "Hypothalamic-Pituitary-IGF1 Growth Axis Evaluation in MVA", | |
| "description": "Endocrine hormone levels, growth hormone responsiveness, and cellular growth resistance indices.", | |
| "row_count": 4, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_15_craniofacial_metrics", | |
| "category": "Clinical & Phenomics", | |
| "title": "Craniofacial Dysmorphic Measurements & Anthropometric Facial Indices", | |
| "description": "Facial landmark dimensions, canthal distances, and palpebral fissure measurements.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_16_ophthalmic_cataracts_screen", | |
| "category": "Clinical & Phenomics", | |
| "title": "Ophthalmic & Retinal Aneuploidy Manifestation Screen", | |
| "description": "Slit-lamp examination, corneal diameter, fundoscopy, and visual evoked potential findings.", | |
| "row_count": 4, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_17_cardiovascular_echocardiogram", | |
| "category": "Clinical & Phenomics", | |
| "title": "Congenital Cardiovascular Screening & Echocardiography Matrix", | |
| "description": "Doppler echocardiography, great vessel branching, and valvular structural evaluation in proband.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_18_lymphocyte_senescence", | |
| "category": "Clinical & Phenomics", | |
| "title": "Immune System T/B Cell Senescence & Lymphocyte Kinetics", | |
| "description": "Flow cytometry lymphocyte subsets, immunoglobulin levels, and cellular senescence markers in MVA.", | |
| "row_count": 6, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_19_dermatoglyphics_palmar_crease", | |
| "category": "Clinical & Phenomics", | |
| "title": "Dermatoglyphic Patterns & Minor Physical Aneuploidy Anomaly Audit", | |
| "description": "Palmar crease patterns, fingertip ridge configurations, and axial triradius positions.", | |
| "row_count": 4, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_20_hepatic_function_matrix", | |
| "category": "Clinical & Phenomics", | |
| "title": "Hepatic Parenchymal Function & Microvesicular Stability Matrix", | |
| "description": "Liver enzymes, synthetic coagulopathy markers, and ultrasound parenchymal assessment in MVA.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_21_gastrointestinal_motility", | |
| "category": "Clinical & Phenomics", | |
| "title": "Gastrointestinal Autonomic Innervation & Motility Biomarkers", | |
| "description": "Enteric neuronal migration, abdominal radiograph findings, and caloric absorption kinetics.", | |
| "row_count": 4, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_22_adrenal_stress_cortisol", | |
| "category": "Clinical & Phenomics", | |
| "title": "Adrenocortical Function & Stress Response Biomarker Profile", | |
| "description": "Basal cortisol, ACTH stimulation, and mineralocorticoid steroidogenesis in proband.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_23_radiosensitivity_guidelines", | |
| "category": "Clinical & Phenomics", | |
| "title": "Constitutional Radiosensitivity & Diagnostic Genotoxic Precautions", | |
| "description": "Radiation exposure safety thresholds, chromosomal break induction, and imaging guidelines for MVA.", | |
| "row_count": 4, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_24_familial_recurrence_counseling", | |
| "category": "Clinical & Phenomics", | |
| "title": "Autosomal Recessive vs De Novo Germline Mosaicism Recurrence Risk", | |
| "description": "Mendelian inheritance models, parental carrier status, and recurrence risk for future pregnancies.", | |
| "row_count": 4, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "clin_25_bayesian_differential_model", | |
| "category": "Clinical & Phenomics", | |
| "title": "Multi-Feature Bayesian Diagnostic Posterior Probability Model", | |
| "description": "Bayesian posterior likelihood cross-matching for 12 rare syndromes presenting with growth restriction and tumors.", | |
| "row_count": 8, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Clinical", | |
| "Phenomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr1_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR1 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Largest autosome; contains CENPF corona kinesin-adapter and 1p36 subtelomeric fragile region. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR1.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr1", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr2_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR2 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Harbors BUB1 kinetochore kinase and ancient 2q13 hominid fusion telomeric junction. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR2.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr2", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr3_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR3 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Harbors FRA3B common fragile site; high sensitivity to aphidicolin replication stress. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR3.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr3", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr4_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR4 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Key checkpoint chromosome; encodes MAD2L1 spindle clamp and CENPE plus-end motor. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR4.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr4", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr5_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR5 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Critical MVA3 locus; harbors TRIP13 AAA+ ATPase disassembler and 5p telomerase core. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR5.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr5", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr6_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR6 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "MHC immunological cluster and FRA6E fragile site; high somatic copy-number stability. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR6.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr6", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr7_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR7 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Encodes MAD1L1 kinetochore anchor dimer; frequent aneuploid missegregation in MVA. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR7.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr7", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr8_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR8 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "High constitutional trisomy 8 variegation in MVA lymphocytes; MYC oncogene hub. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR8.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr8", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr9_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR9 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Encodes SMC5 chromosome decatenation subunit and 9q12 Satellite III pericentric heterochromatin. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR9.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr9", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr10_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR10 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Encodes BUB3 WD40 propeller scaffold and ZWINT KNL1-docking structural component. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR10.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr10", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr11_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR11 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Critical MVA2 locus; encodes CEP57 centriolar anchor and 11p15.5 imprinting cluster. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR11.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr11", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr12_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR12 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "12q14 amplicon hub; harbors KRAS signaling and CDK4/MDM2 cell cycle machinery. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR12.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr12", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr13_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR13 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Acrocentric autosome with NOR rDNA arrays; harbors RB1 tumor suppressor and FOXO1 RMS locus. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR13.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr13", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr14_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR14 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Encodes DICER1 microRNA processing endoribonuclease and immunoglobulin heavy chain locus. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR14.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr14", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr15_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR15 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Primary MVA1 master locus; encodes BUB1B/BUBR1 spindle assembly checkpoint kinase. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR15.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr15", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr16_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR16 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Encodes PLK1 Polo-like master mitotic kinase and 16q23.2 FRA16D fragile region. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR16.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr16", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr17_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR17 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Harbors TP53 guardian of the genome; frequent 17p LOH in rhabdomyosarcoma progression. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR17.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr17", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr18_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR18 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Critical MVA4 locus; encodes CEP192 pericentriolar PCM scaffold and Aurora A recruiter. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR18.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr18", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr19_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR19 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Highest gene and variant density in human genome (1,922 / Mb); GC-rich isochore core. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR19.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr19", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr20_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR20 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Encodes AURKA Aurora Kinase A; centrosome maturation and spindle bipolarity hub. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR20.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr20", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr21_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR21 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Smallest acrocentric autosome; Down syndrome critical region and Robertsonian partner. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR21.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr21", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chr22_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHR22 Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Acrocentric chromosome; encodes CHEK2 checkpoint kinase and BCR-ABL translocation site. Analysis of variant density, SNV/Indel balance, and candidate loci on CHR22.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chr22", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chrX_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHRX Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Sex chromosome; subject to X-inactivation; frequent variegated loss in MVA lymphocytes. Analysis of variant density, SNV/Indel balance, and candidate loci on CHRX.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chrX", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_chrY_structural_architecture", | |
| "category": "Chromosome Architecture", | |
| "title": "Chromosome CHRY Fine-Grained Architecture & Locus Dynamics", | |
| "description": "Heterochromatic male sex chromosome; high somatic loss-of-Y (LOY) rate in aneuploid clones. Analysis of variant density, SNV/Indel balance, and candidate loci on CHRY.", | |
| "row_count": 5, | |
| "columns_count": 5, | |
| "tags": [ | |
| "Chromosome", | |
| "chrY", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "chr_cin70_burden_scores", | |
| "category": "Chromosome Architecture", | |
| "title": "CIN70 Chromosomal Instability Mutational Signature Scoring", | |
| "description": "Mutational burden, VAF values, and GATK quality metrics across the classic 70-gene CIN70 signature.", | |
| "row_count": 9, | |
| "columns_count": 6, | |
| "tags": [ | |
| "CIN70", | |
| "Chromosomal Instability", | |
| "Signatures" | |
| ] | |
| }, | |
| { | |
| "id": "chr_cosmic_sbs_profiles", | |
| "category": "Chromosome Architecture", | |
| "title": "COSMIC Single Base Substitution (SBS) Mutational Signatures in MVA", | |
| "description": "Decomposition of patient whole-genome SNV callset into standard COSMIC v3.3 trinucleotide mutational signatures.", | |
| "row_count": 5, | |
| "columns_count": 6, | |
| "tags": [ | |
| "COSMIC", | |
| "Mutational Signatures", | |
| "Trinucleotide" | |
| ] | |
| }, | |
| { | |
| "id": "chr_cn_loh_recombination_map", | |
| "category": "Chromosome Architecture", | |
| "title": "Segmental Copy-Neutral Loss-of-Heterozygosity (CN-LOH) Loci", | |
| "description": "Contiguous homozygous variant stretches identifying mitotic recombination and uniparental disomy intervals.", | |
| "row_count": 5, | |
| "columns_count": 6, | |
| "tags": [ | |
| "LOH", | |
| "Mitotic Recombination", | |
| "Copy Neutral" | |
| ] | |
| }, | |
| { | |
| "id": "chr_pericentromeric_satellite_fragility", | |
| "category": "Chromosome Architecture", | |
| "title": "Pericentromeric Heterochromatin Satellite Repeat Fragility Audit", | |
| "description": "Satellite II/III repeat stability, classical centromere constriction, and pericentromeric variant clustering.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Heterochromatin", | |
| "Pericentromere", | |
| "Satellite Repeats" | |
| ] | |
| }, | |
| { | |
| "id": "chr_subtelomeric_recomb_caps", | |
| "category": "Chromosome Architecture", | |
| "title": "Subtelomeric Recombination Hotspots & Terminal Cap Integrity", | |
| "description": "Terminal 2Mb repeat content, telomeric variant density, and subtelomeric rearrangement hotspots.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Subtelomeres", | |
| "Recombination", | |
| "Caps" | |
| ] | |
| }, | |
| { | |
| "id": "chr_cfs_breakage_indices", | |
| "category": "Chromosome Architecture", | |
| "title": "Common Fragile Sites (CFS) Breakage Susceptibility Index", | |
| "description": "Genomic coordinates of aphidicolin-sensitive common fragile sites and structural break vulnerability in MVA.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Fragile Sites", | |
| "Replication Stress", | |
| "Breaks" | |
| ] | |
| }, | |
| { | |
| "id": "mit_bub1b_pseudokinase_clamp", | |
| "category": "Gene Panels & Interactome", | |
| "title": "BUB1B / BUBR1 Pseudokinase Domain & CDC20 Clamping Kinetics", | |
| "description": "BUBR1 TPR motifs, KARD phospho-domain, and CDC20 binding clamp.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "BUB1B" | |
| ] | |
| }, | |
| { | |
| "id": "mit_cep57_centriole_inner_barrel", | |
| "category": "Gene Panels & Interactome", | |
| "title": "CEP57 Centriolar Inner Barrel Attachment & Tubulin Nucleation", | |
| "description": "CEP57 coiled-coil inner wall anchoring and MVA2 nephrocalcinosis.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CEP57" | |
| ] | |
| }, | |
| { | |
| "id": "mit_trip13_aaa_atpase_hexamer", | |
| "category": "Gene Panels & Interactome", | |
| "title": "TRIP13 AAA+ ATPase Hexameric Disassembly Engine", | |
| "description": "ATP-dependent unfolding of C-MAD2 and mosaic somatic driver mechanics.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "TRIP13" | |
| ] | |
| }, | |
| { | |
| "id": "mit_cep192_pcm_aurora_recruitment", | |
| "category": "Gene Panels & Interactome", | |
| "title": "CEP192 Pericentriolar Matrix Scaffold & Kinase Co-Recruitment", | |
| "description": "Centrosomal recruitment of AURKA and PLK1 in spindle bipolarity.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CEP192" | |
| ] | |
| }, | |
| { | |
| "id": "mit_mad1l1_kinetochore_docking", | |
| "category": "Gene Panels & Interactome", | |
| "title": "MAD1L1 Coiled-Coil Dimerization & Kinetochore Corona Anchor", | |
| "description": "MAD1-MAD2 catalytic template and corona expansion.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "MAD1L1" | |
| ] | |
| }, | |
| { | |
| "id": "mit_mad2l1_topological_safety_belt", | |
| "category": "Gene Panels & Interactome", | |
| "title": "MAD2L1 Topological Clamp & CDC20 Entrapment Dynamics", | |
| "description": "Open-to-closed conformer transition and APC/C inhibition.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "MAD2L1" | |
| ] | |
| }, | |
| { | |
| "id": "mit_bub1_melt_phospho_cascade", | |
| "category": "Gene Panels & Interactome", | |
| "title": "BUB1 Kinase & KNL1 MELT Phosphorylation Hierarchy", | |
| "description": "Multi-site phosphorylation of KNL1 coordinating outer kinetochore assembly.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "BUB1" | |
| ] | |
| }, | |
| { | |
| "id": "mit_bub3_wd40_beta_propeller", | |
| "category": "Gene Panels & Interactome", | |
| "title": "BUB3 7-Bladed WD40 \u03b2-Propeller & Phospho-MELT Reader", | |
| "description": "Structural recognition of phosphorylated MELT motifs on KNL1.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "BUB3" | |
| ] | |
| }, | |
| { | |
| "id": "mit_cenpe_kinesin7_translocation", | |
| "category": "Gene Panels & Interactome", | |
| "title": "CENPE Kinesin-7 Motor Mechanics & Chromosome Congression", | |
| "description": "Single-molecule stepping kinetics and metaphase alignment.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CENPE" | |
| ] | |
| }, | |
| { | |
| "id": "mit_cenpf_corona_farnesylation", | |
| "category": "Gene Panels & Interactome", | |
| "title": "CENPF C-Terminal Farnesylation & Dynein Cargo Coupling", | |
| "description": "Outer corona structural expansion and Dynein-Dynactin recruitment.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CENPF" | |
| ] | |
| }, | |
| { | |
| "id": "mit_aurka_tpx2_spindle_bipolarity", | |
| "category": "Gene Panels & Interactome", | |
| "title": "Aurora Kinase A - TPX2 Allosteric Spindle Pole Organizer", | |
| "description": "Centrosome maturation, spindle pole separation, and bipolarity.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "AURKA" | |
| ] | |
| }, | |
| { | |
| "id": "mit_plk1_polo_box_substrate_docking", | |
| "category": "Gene Panels & Interactome", | |
| "title": "PLK1 Polo-Box Domain Phosphopeptide Recognition", | |
| "description": "Polo-box phosphopeptide docking and mitotic entry orchestration.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "PLK1" | |
| ] | |
| }, | |
| { | |
| "id": "mit_smc5_smc6_cohesin_decatenation", | |
| "category": "Gene Panels & Interactome", | |
| "title": "SMC5/6 Complex & Post-Replicative Decatenation Checkpoint", | |
| "description": "Topoisomerase II assistance and chromosome arm resolution.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "SMC5" | |
| ] | |
| }, | |
| { | |
| "id": "mit_rad21_stag2_sister_cohesion", | |
| "category": "Gene Panels & Interactome", | |
| "title": "RAD21 / STAG2 Cohesin Ring Structure & Separase Cleavage", | |
| "description": "Centromeric sister chromatid cohesion and anaphase trigger.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "RAD21" | |
| ] | |
| }, | |
| { | |
| "id": "mit_sgo1_shugoshin_pp2a_protection", | |
| "category": "Gene Panels & Interactome", | |
| "title": "SGO1 (Shugoshin) / PP2A Centromeric Cohesion Protector", | |
| "description": "Protection of centromeric cohesin against prophase removal pathway.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "SGO1" | |
| ] | |
| }, | |
| { | |
| "id": "mit_haspin_histone_h3t3_cpc_docking", | |
| "category": "Gene Panels & Interactome", | |
| "title": "Haspin Kinase Phosphorylation of H3T3 & CPC Kinetochore Docking", | |
| "description": "Centromeric targeting of the Chromosomal Passenger Complex (CPC).", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "HASPIN" | |
| ] | |
| }, | |
| { | |
| "id": "mit_aurkb_borealin_survivin_incenp", | |
| "category": "Gene Panels & Interactome", | |
| "title": "Aurora B Chromosomal Passenger Complex (CPC) Tension Sensing", | |
| "description": "Phosphorylation of Ndc80 tail and error correction of syntelic attachments.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "AURKB" | |
| ] | |
| }, | |
| { | |
| "id": "mit_mps1_ttk_activation_loop", | |
| "category": "Gene Panels & Interactome", | |
| "title": "MPS1 / TTK Kinase Autophosphorylation & Checkpoint Initiation", | |
| "description": "Kinetochore recruitment and MELT phosphorylation initiation.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "MPS1" | |
| ] | |
| }, | |
| { | |
| "id": "mit_zw10_rod_zwilch_rzz_complex", | |
| "category": "Gene Panels & Interactome", | |
| "title": "RZZ Complex (ROD-ZW10-Zwilch) & Kinetochore Corona Assembly", | |
| "description": "Outer corona expansion and Spindly-Dynein adapter docking.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "ZW10" | |
| ] | |
| }, | |
| { | |
| "id": "mit_spindly_dynein_sac_stripping", | |
| "category": "Gene Panels & Interactome", | |
| "title": "Spindly Adapter & Dynein-Mediated Checkpoint Protein Stripping", | |
| "description": "Mechanical transport of MAD2/BUBR1 along microtubules to centrosomes.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "SPINDLY" | |
| ] | |
| }, | |
| { | |
| "id": "mit_apc_c_cdc20_cdh1_degron_selection", | |
| "category": "Gene Panels & Interactome", | |
| "title": "APC/C E3 Ubiquitin Ligase D-Box & KEN-Box Degron Selection", | |
| "description": "Ubiquitination of Securin and Cyclin B1 for anaphase onset.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "APC" | |
| ] | |
| }, | |
| { | |
| "id": "mit_securin_pttgl1_separase_inhibitor", | |
| "category": "Gene Panels & Interactome", | |
| "title": "Securin (PTTG1) Degradation & Separase Protease Activation", | |
| "description": "Release of active Separase to cleave RAD21 cohesin rings.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "SECURIN" | |
| ] | |
| }, | |
| { | |
| "id": "mit_cyclin_b1_ccnb1_cdk1_clearance", | |
| "category": "Gene Panels & Interactome", | |
| "title": "Cyclin B1 / CDK1 Kinase Clearance Dynamics at Metaphase Exit", | |
| "description": "Dephosphorylation cascade driving mitotic spindle disassembly.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CYCLIN" | |
| ] | |
| }, | |
| { | |
| "id": "mit_p31comet_mad2l1bp_trip13_dock", | |
| "category": "Gene Panels & Interactome", | |
| "title": "p31(comet) Adapter Docking to Closed-MAD2 for TRIP13 Unfolding", | |
| "description": "Structural adapter driving SAC silencing and checkpoint inactivation.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "P31COMET" | |
| ] | |
| }, | |
| { | |
| "id": "mit_ndc80_hec1_microtubule_coupling", | |
| "category": "Gene Panels & Interactome", | |
| "title": "Ndc80 (Hec1) Microtubule Coupling & Tension Elasticity", | |
| "description": "Calponin homology domain binding to tubulin protofilaments.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "NDC80" | |
| ] | |
| }, | |
| { | |
| "id": "mit_knl1_casc5_melt_array_scaffold", | |
| "category": "Gene Panels & Interactome", | |
| "title": "KNL1 (CASC5) Multiple MELT Repeat Structural Scaffold", | |
| "description": "Intrinsically disordered docking platform for BUB3-BUBR1 complexes.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "KNL1" | |
| ] | |
| }, | |
| { | |
| "id": "mit_mis12_dsn1_nsl1_pmf1_linker", | |
| "category": "Gene Panels & Interactome", | |
| "title": "Mis12 Complex Molecular Linker Between CENP-C and Ndc80", | |
| "description": "Four-subunit bridging complex connecting inner centromere to outer plate.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "MIS12" | |
| ] | |
| }, | |
| { | |
| "id": "mit_cenpa_histone_h3_variant_nucleosome", | |
| "category": "Gene Panels & Interactome", | |
| "title": "CENP-A Centromeric Histone H3 Variant & Epigenetic Centromere", | |
| "description": "Epigenetic specification of kinetochore assembly loci on satellite DNA.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CENPA" | |
| ] | |
| }, | |
| { | |
| "id": "mit_cenpc_inner_kinetochore_cup", | |
| "category": "Gene Panels & Interactome", | |
| "title": "CENP-C Central Kinetochore Hub & Mis12-CENPA Bridging", | |
| "description": "Direct interaction bridging CENP-A nucleosomes to outer Mis12 complex.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CENPC" | |
| ] | |
| }, | |
| { | |
| "id": "mit_cenpt_inner_kinetochore_pathway", | |
| "category": "Gene Panels & Interactome", | |
| "title": "CENP-T Centromeric DNA-Binding & Direct Ndc80 Recruitment", | |
| "description": "Alternative non-Mis12 pathway for outer kinetochore microtubule tethering.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CENPT" | |
| ] | |
| }, | |
| { | |
| "id": "mit_kif2c_mcak_microtubule_depolymerase", | |
| "category": "Gene Panels & Interactome", | |
| "title": "KIF2C (MCAK) Kinetochore Microtubule Depolymerase", | |
| "description": "Error correction of merotelic and syntelic microtubule-kinetochore attachments.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "KIF2C" | |
| ] | |
| }, | |
| { | |
| "id": "mit_clasp1_clasp2_microtubule_plus_end", | |
| "category": "Gene Panels & Interactome", | |
| "title": "CLASP1 / CLASP2 Kinetochore Plus-End Microtubule Rescuers", | |
| "description": "Promotion of microtubule rescue and stabilization under tension.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CLASP1" | |
| ] | |
| }, | |
| { | |
| "id": "mit_kif18a_kinesin8_length_dependent_motor", | |
| "category": "Gene Panels & Interactome", | |
| "title": "KIF18A Kinesin-8 Length-Dependent Microtubule Depolymerase", | |
| "description": "Dampening of chromosome oscillations and metaphase alignment confinement.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "KIF18A" | |
| ] | |
| }, | |
| { | |
| "id": "mit_chmp4b_escrt_iii_micronucleus_repair", | |
| "category": "Gene Panels & Interactome", | |
| "title": "ESCRT-III (CHMP4B) Micronuclear Envelope Repair Complex", | |
| "description": "Sealing of ruptured micronuclear envelopes to prevent DNA damage.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "CHMP4B" | |
| ] | |
| }, | |
| { | |
| "id": "mit_trex1_micronuclear_dna_exonuclease", | |
| "category": "Gene Panels & Interactome", | |
| "title": "TREX1 Endoplasmic Reticulum DNA Exonuclease & cGAS Degradation", | |
| "description": "Cleavage of shattered micronuclear DNA fragments upon envelope collapse.", | |
| "row_count": 3, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Gene Panel", | |
| "Mitotic Checkpoint", | |
| "TREX1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_01", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 01: TRIP13 c.1060G>A (27.8% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for TRIP13 c.1060G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "TRIP13" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_02", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 02: BUB1B c.1972C>T (51.4% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for BUB1B c.1972C>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "BUB1B" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_03", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 03: CEP57 c.403C>T (51.4% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for CEP57 c.403C>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "CEP57" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_04", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 04: MAD1L1 c.1852C>T (22.2% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for MAD1L1 c.1852C>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "MAD1L1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_05", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 05: CEP192 c.1504G>A (18.5% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for CEP192 c.1504G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "CEP192" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_06", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 06: TP53 c.524G>A (34.2% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for TP53 c.524G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "TP53" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_07", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 07: WT1 c.1180C>T (14.8% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for WT1 c.1180C>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "WT1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_08", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 08: DICER1 c.5438A>G (11.2% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for DICER1 c.5438A>G.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "DICER1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_09", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 09: CENPE c.7123G>A (48.9% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for CENPE c.7123G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "CENPE" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_10", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 10: CENPF c.5461C>T (16.4% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for CENPF c.5461C>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "CENPF" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_11", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 11: PLK1 c.628G>A (9.5% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for PLK1 c.628G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "PLK1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_12", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 12: AURKA c.883A>G (100.0% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for AURKA c.883A>G.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "AURKA" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_13", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 13: SMC5 c.1441G>A (8.2% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for SMC5 c.1441G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "SMC5" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_14", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 14: RAD21 c.1105C>T (6.4% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for RAD21 c.1105C>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "RAD21" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_15", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 15: SGO1 c.892A>G (5.1% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for SGO1 c.892A>G.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "SGO1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_16", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 16: MPS1 c.2026A>T (4.3% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for MPS1 c.2026A>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "MPS1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_17", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 17: ZWINT c.421G>A (3.8% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for ZWINT c.421G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "ZWINT" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_18", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 18: KIF2C c.1684C>T (42.1% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for KIF2C c.1684C>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "KIF2C" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_19", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 19: CLASP1 c.2842G>A (31.5% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for CLASP1 c.2842G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "CLASP1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_20", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 20: KIF18A c.1340A>G (25.0% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for KIF18A c.1340A>G.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "KIF18A" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_21", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 21: CHMP4B c.412C>T (19.8% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for CHMP4B c.412C>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "CHMP4B" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_22", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 22: TREX1 c.589G>A (13.5% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for TREX1 c.589G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "TREX1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_23", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 23: BUB3 c.385A>G (7.8% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for BUB3 c.385A>G.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "BUB3" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_24", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 24: MAD2L1 c.398G>A (52.1% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for MAD2L1 c.398G>A.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "MAD2L1" | |
| ] | |
| }, | |
| { | |
| "id": "mos_strata_vaf_bin_25", | |
| "category": "Mosaicism Spectrum", | |
| "title": "Mosaicism Stratum 25: APC c.4348C>T (2.9% VAF) Lineage Profile", | |
| "description": "Allelic fraction quantification, sequencing read support, and lineage allocation for APC c.4348C>T.", | |
| "row_count": 4, | |
| "columns_count": 7, | |
| "tags": [ | |
| "Mosaicism", | |
| "VAF", | |
| "APC" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_01", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "AlphaMissense Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for AlphaMissense.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "AlphaMissense" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_02", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "REVEL Ensemble Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for REVEL Ensemble.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "REVEL" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_03", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "CADD Phred v1.6 Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for CADD Phred v1.6.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "CADD" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_04", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "SpliceAI CNN Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for SpliceAI CNN.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "SpliceAI" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_05", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "PrimateAI-3D Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for PrimateAI-3D.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "PrimateAI-3D" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_06", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "ESM-1b Transformer Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for ESM-1b Transformer.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "ESM-1b" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_07", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "ClinPred Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for ClinPred.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "ClinPred" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_08", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "MPC Sub-Genic Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for MPC Sub-Genic.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "MPC" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_09", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "MTR Sliding Window Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for MTR Sliding Window.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "MTR" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_10", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "GERP++ Conservation Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for GERP++ Conservation.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "GERP++" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_11", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "PhyloP 100-Way Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for PhyloP 100-Way.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "PhyloP" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_12", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "PhastCons Mammals Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for PhastCons Mammals.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "PhastCons" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_13", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "MutationTaster2 Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for MutationTaster2.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "MutationTaster2" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_14", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "FATHMM-XF Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for FATHMM-XF.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "FATHMM-XF" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_15", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "PROVEAN Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for PROVEAN.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "PROVEAN" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_16", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "SIFT4G Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for SIFT4G.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "SIFT4G" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_17", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "PolyPhen-2 HVAR Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for PolyPhen-2 HVAR.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "PolyPhen-2" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_18", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "VEST4 Forest Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for VEST4 Forest.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "VEST4" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_19", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "MetaSVM Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for MetaSVM.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "MetaSVM" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_20", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "MetaLR Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for MetaLR.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "MetaLR" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_21", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "BayesDel Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for BayesDel.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "BayesDel" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_22", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "LRT Conservation Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for LRT Conservation.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "LRT" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_23", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "DANN Deep Net Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for DANN Deep Net.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "DANN" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_24", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "Eigen-PC Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for Eigen-PC.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "Eigen-PC" | |
| ] | |
| }, | |
| { | |
| "id": "acmg_predictor_evaluation_25", | |
| "category": "ACMG & In Silico Predictors", | |
| "title": "GenoCanyon Pathogenicity Calibration & Machine Learning Performance", | |
| "description": "Deleterious threshold calibrations, specificity, and ROC performance for GenoCanyon.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "ACMG", | |
| "InSilico", | |
| "GenoCanyon" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_01", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 01: Alisertib (MLN8237) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Alisertib (MLN8237).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Alisertib" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_02", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 02: Volasertib (BI 6727) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Volasertib (BI 6727).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Volasertib" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_03", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 03: CFI-402257 Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for CFI-402257.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "CFI-402257" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_04", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 04: Talazoparib (BMN 673) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Talazoparib (BMN 673).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Talazoparib" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_05", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 05: Olaparib (AZD2281) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Olaparib (AZD2281).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Olaparib" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_06", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 06: Milademetan (RAIN-32) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Milademetan (RAIN-32).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Milademetan" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_07", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 07: Vincristine Sulfate Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Vincristine Sulfate.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Vincristine" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_08", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 08: Cyclophosphamide Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Cyclophosphamide.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Cyclophosphamide" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_09", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 09: Dactinomycin Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Dactinomycin.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Dactinomycin" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_10", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 10: Dinaciclib (SCH 727965) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Dinaciclib (SCH 727965).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Dinaciclib" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_11", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 11: Adavosertib (MK-1775) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Adavosertib (MK-1775).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Adavosertib" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_12", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 12: Berzosertib (VX-970) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Berzosertib (VX-970).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Berzosertib" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_13", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 13: M3541 Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for M3541.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "M3541" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_14", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 14: Prexasertib (LY2606368) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Prexasertib (LY2606368).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Prexasertib" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_15", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 15: KIF18A Inhibitor CW069 Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for KIF18A Inhibitor CW069.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "KIF18A" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_16", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 16: KIFC1 / HSET Inhibitor Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for KIFC1 / HSET Inhibitor.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "KIFC1" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_17", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 17: GSK923295 Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for GSK923295.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "GSK923295" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_18", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 18: Bortezomib (PS-341) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Bortezomib (PS-341).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Bortezomib" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_19", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 19: Hydroxychloroquine Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Hydroxychloroquine.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Hydroxychloroquine" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_20", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 20: ADU-S100 (MIW815) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for ADU-S100 (MIW815).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "ADU-S100" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_21", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 21: Pembrolizumab Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Pembrolizumab.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Pembrolizumab" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_22", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 22: Selinexor (KPT-330) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Selinexor (KPT-330).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Selinexor" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_23", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 23: Vorinostat (SAHA) Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for Vorinostat (SAHA).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "Vorinostat" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_24", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 24: JQ1 BET Inhibitor Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for JQ1 BET Inhibitor.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "JQ1" | |
| ] | |
| }, | |
| { | |
| "id": "pharm_oncology_profile_25", | |
| "category": "Precision Oncology & Pharma", | |
| "title": "Precision Oncology Stratum 25: ARV-110 PROTAC Pharmacology & Synergy", | |
| "description": "Cellular IC50 potency, synthetic lethality mechanism, and safety considerations for ARV-110 PROTAC.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Pharmacology", | |
| "Oncology", | |
| "ARV-110" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_01", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 01: Premature Centromere Division (PCD) Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Premature Centromere Division (PCD).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Premature" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_02", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 02: Chromosome Missegregation Rate Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Chromosome Missegregation Rate.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Chromosome" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_03", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 03: Micronucleus Frequency Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Micronucleus Frequency.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Micronucleus" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_04", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 04: Multipolar Spindle Frequency Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Multipolar Spindle Frequency.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Multipolar" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_05", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 05: Sister Chromatid Exchange (SCE) Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Sister Chromatid Exchange (SCE).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Sister" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_06", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 06: Tetraploid Endoreduplication Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Tetraploid Endoreduplication.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Tetraploid" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_07", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 07: Acrocentric Satellite Association Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Acrocentric Satellite Association.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Acrocentric" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_08", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 08: Sex Chromosome Variegation Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Sex Chromosome Variegation.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Sex" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_09", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 09: Fragile Site Gaps (Aphidicolin) Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Fragile Site Gaps (Aphidicolin).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Fragile" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_10", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 10: Centromeric Cohesion Loss Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Centromeric Cohesion Loss.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Centromeric" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_11", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 11: Radial Nuclear Organization Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Radial Nuclear Organization.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Radial" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_12", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 12: Mitotic Index (MI%) Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Mitotic Index (MI%).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Mitotic" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_13", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 13: Telomere PNA-FISH Variance Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Telomere PNA-FISH Variance.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Telomere" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_14", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 14: Alpha-Satellite Repeat Arrays Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Alpha-Satellite Repeat Arrays.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Alpha-Satellite" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_15", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 15: TREX1 Ruptured Micronuclei Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for TREX1 Ruptured Micronuclei.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "TREX1" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_16", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 16: Death-in-Mitosis vs Slippage Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Death-in-Mitosis vs Slippage.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Death-in-Mitosis" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_17", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 17: Phylogenetic Karyotype Subtrees Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Phylogenetic Karyotype Subtrees.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Phylogenetic" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_18", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 18: KIFC1 Clustering Capacity Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for KIFC1 Clustering Capacity.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "KIFC1" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_19", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 19: Chromothripsis Reintegration Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Chromothripsis Reintegration.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Chromothripsis" | |
| ] | |
| }, | |
| { | |
| "id": "cyto_karyotype_phenotype_20", | |
| "category": "Cytogenetics & Aneuploidy", | |
| "title": "Cytogenetic Assay 20: Dicentric Bridge-Fusion Cycles Quantification", | |
| "description": "Quantitative cytogenetic parameters, metaphase counts, and clinical correlations for Dicentric Bridge-Fusion Cycles.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Cytogenetics", | |
| "Karyotype", | |
| "Dicentric" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_01", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 01: Lane L001 Microfluidics", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Lane L001 Microfluidics.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Lane" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_02", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 02: Lane L002 Dual-Laser Optics", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Lane L002 Dual-Laser Optics.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Lane" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_03", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 03: Lane L003 Thermal Peltier", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Lane L003 Thermal Peltier.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Lane" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_04", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 04: Lane L004 TDI Sensor Imaging", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Lane L004 TDI Sensor Imaging.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Lane" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_05", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 05: Forward Read 1 Quality", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Forward Read 1 Quality.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Forward" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_06", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 06: Reverse Read 2 Phasing", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Reverse Read 2 Phasing.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Reverse" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_07", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 07: TruSeq Adapter Trimming", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for TruSeq Adapter Trimming.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "TruSeq" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_08", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 08: Library Duplication Rate", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Library Duplication Rate.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Library" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_09", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 09: Insert Size Distribution", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Insert Size Distribution.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Insert" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_10", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 10: BWA-MEM GRCh38 Alignment", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for BWA-MEM GRCh38 Alignment.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "BWA-MEM" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_11", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 11: GATK BQSR Recalibration", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for GATK BQSR Recalibration.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "GATK" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_12", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 12: Exonic Coverage Uniformity", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Exonic Coverage Uniformity.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Exonic" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_13", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 13: GC Bias Coverage Curve", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for GC Bias Coverage Curve.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "GC" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_14", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 14: Mismatch Noise Floor", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Mismatch Noise Floor.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Mismatch" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_15", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 15: Indel Size Distribution", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Indel Size Distribution.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Indel" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_16", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 16: Ti/Tv Mutation Ratio", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Ti/Tv Mutation Ratio.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Ti/Tv" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_17", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 17: dbSNP 156 Concordance", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for dbSNP 156 Concordance.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "dbSNP" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_18", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 18: Chimeric Split-Reads", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Chimeric Split-Reads.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Chimeric" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_19", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 19: Soft-Clipped Read Clusters", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Soft-Clipped Read Clusters.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Soft-Clipped" | |
| ] | |
| }, | |
| { | |
| "id": "qc_telemetry_matrix_20", | |
| "category": "Sequencing & Flowcell QC", | |
| "title": "Flowcell Telemetry 20: Flowcell Master COA", | |
| "description": "Detailed sequencing quality metrics, physical telemetry, and compliance benchmarks for Flowcell Master COA.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Sequencing QC", | |
| "NovaSeq", | |
| "Flowcell" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_01", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 01: TRIP13 AAA+ Hexamer Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for TRIP13 AAA+ Hexamer.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "TRIP13" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_02", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 02: CENPE Kinesin-7 Motor Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for CENPE Kinesin-7 Motor.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "CENPE" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_03", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 03: MAD1-MAD2 Dimerization Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for MAD1-MAD2 Dimerization.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "MAD1-MAD2" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_04", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 04: Aurora A - TPX2 Complex Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for Aurora A - TPX2 Complex.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "Aurora" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_05", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 05: PLK1 Polo-Box Domain Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for PLK1 Polo-Box Domain.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "PLK1" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_06", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 06: BUBR1-CDC20 Complex Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for BUBR1-CDC20 Complex.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "BUBR1-CDC20" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_07", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 07: KNL1 Multi-MELT Array Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for KNL1 Multi-MELT Array.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "KNL1" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_08", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 08: Ndc80 Complex Tail Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for Ndc80 Complex Tail.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "Ndc80" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_09", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 09: Spindle Microtubules Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for Spindle Microtubules.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "Spindle" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_10", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 10: Separase Protease Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for Separase Protease.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "Separase" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_11", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 11: Centrosomal PCM (CEP192) Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for Centrosomal PCM (CEP192).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "Centrosomal" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_12", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 12: Chromatin Elastic Fiber Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for Chromatin Elastic Fiber.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "Chromatin" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_13", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 13: Centriolar Transition Zone Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for Centriolar Transition Zone.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "Centriolar" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_14", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 14: cGAS Micronuclear Condensation Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for cGAS Micronuclear Condensation.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "cGAS" | |
| ] | |
| }, | |
| { | |
| "id": "bio_kinetics_matrix_15", | |
| "category": "Biophysical Kinetics", | |
| "title": "Biophysical Parameter 15: Cellular ATP Consumption Mechanics", | |
| "description": "Nanomechanical measurements, thermodynamic free energies, and cellular kinetics for Cellular ATP Consumption.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Biophysics", | |
| "Kinetics", | |
| "Cellular" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_01", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 01: St. Jude Children's Research Hospital", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from St. Jude Children's Research Hospital.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "St." | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_02", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 02: NCI TARGET Pan-Cancer Project", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from NCI TARGET Pan-Cancer Project.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "NCI" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_03", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 03: International MVA Syndrome Registry", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from International MVA Syndrome Registry.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "International" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_04", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 04: TCGA Soft Tissue Sarcoma Cohort", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from TCGA Soft Tissue Sarcoma Cohort.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "TCGA" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_05", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 05: ICGC Pediatric Brain Tumor Consortium", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from ICGC Pediatric Brain Tumor Consortium.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "ICGC" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_06", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 06: Children's Oncology Group (COG) ARST", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from Children's Oncology Group (COG) ARST.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "Children's" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_07", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 07: DECIPHER Rare Disease Database", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from DECIPHER Rare Disease Database.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "DECIPHER" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_08", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 08: Genomics England 100,000 Genomes", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from Genomics England 100,000 Genomes.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "Genomics" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_09", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 09: DepMap Cancer Dependency Map (PRISM)", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from DepMap Cancer Dependency Map (PRISM).", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "DepMap" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_10", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 10: DepMap CRISPR Essentiality Screens", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from DepMap CRISPR Essentiality Screens.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "DepMap" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_11", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 11: COSMIC Cell Lines Project", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from COSMIC Cell Lines Project.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "COSMIC" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_12", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 12: CIViC Clinical Interpretations", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from CIViC Clinical Interpretations.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "CIViC" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_13", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 13: OncoKB Precision Oncology", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from OncoKB Precision Oncology.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "OncoKB" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_14", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 14: RDCA-DAP Rare Disease Cures", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from RDCA-DAP Rare Disease Cures.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "RDCA-DAP" | |
| ] | |
| }, | |
| { | |
| "id": "coh_registry_crossmatch_15", | |
| "category": "Comparative Oncology Cohorts", | |
| "title": "Cohort Cross-Match 15: AACR Project GENIE Registry", | |
| "description": "Comparative genomic frequencies, survival statistics, and precision oncology insights from AACR Project GENIE Registry.", | |
| "row_count": 4, | |
| "columns_count": 6, | |
| "tags": [ | |
| "Comparative Oncology", | |
| "Cohorts", | |
| "AACR" | |
| ] | |
| } | |
| ] | |
| } |